# Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Study · id `cardio:ct-nct04763200` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04763200](<https://clinicaltrials.gov/study/NCT04763200>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04763200

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1252 participants.

## Technical summary

Registry record NCT04763200. Randomized; no masking; primary purpose treatment. Start 2021-04-13 (actual); primary completion 2026-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1252 participants (planned count; ClinicalTrials.gov record NCT04763200, source copy `cardio:ctgov-nct04763200-2026-07-28`, retrieved 2026-10-26)
- Started: 2021-04-13 (actual) (ClinicalTrials.gov record NCT04763200, source copy `cardio:ctgov-nct04763200-2026-07-28`, retrieved 2026-10-26)
- Primary completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT04763200, source copy `cardio:ctgov-nct04763200-2026-07-28`, retrieved 2026-10-26)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT04763200, source copy `cardio:ctgov-nct04763200-2026-07-28`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; Italy; Netherlands; Switzerland; United Kingdom (ClinicalTrials.gov record NCT04763200, source copy `cardio:ctgov-nct04763200-2026-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04763200-2026-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
- Acronym: PROTECT IV
- Condition: Left Ventricular Dysfunction
- Condition: Coronary Artery Disease
- Intervention (Device): Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®
- Intervention (Device): IABP Intra-aortic balloon pump
- Lead sponsor: Abiomed Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry lists this organization as the lead sponsor: Abiomed Inc. (`cardio:org-abiomed-inc`)

## Provenance

Content hash: 897f5e2ab72cf3f6679337bb5f2cf0129e03c37c2f4caa2bd02a102816c083db
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
